Novartis Looks To Extend Top-Selling Cosentyx Into Juvenile Arthritis
Primary Endpoint Met In Phase III JUNIPERA Study
Top-line results from the Phase III JUNIPERA study of Novartis’s IL17A-targeting anti-inflammatory Cosentyx support its use in juvenile idiopathic arthritis, and the company intends to move quickly to enter the marketplace in pediatric patients with two subtypes of the condition.
